Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 2, 2019

View Archived Issues

Umbralisib plus ibrutinib demonstrate safety and activity in patients with leukemia and lymphoma

Methylscape alteration of DNA physicochemical properties can be applied for cancer diagnostic assays

Discovery of osimertinib analogue that selectively inhibits EGFR for NSCLC treatment

Novel selective azaindole TGF-beta receptor kinase inhibitors may improve immuno-oncology therapy

AOH-1160 demonstrates promising anticancer activity without significant toxicity in vivo

Sleeping sickness parasite can make its own sugar

Genetic diversity makes for better Alzheimer's model

ST-8116 demonstrates promising antitumor activity in preclinical models of colon cancer

Epigenetic analysis boosts malaria pathogenesis understanding

Patient enrollment ongoing in phase I study of BOS-172738

NicOx presents new compounds for eye disorders

Chiesi Farmaceutici patents new MAPK 14 inhibitors

Cadila Healthcare synthesizes NLRP3 inhibitors

Hanmi Science describes KDM1A inhibitors

Dosing begins in phase III study of Tyvyt for first-line esophageal squamous cell carcinoma

New PDE9 inhibitors presented by Merck & Co.

ALCAM-EGFR axis discovered as therapeutic target in multiple myeloma

BioCryst doses first patient in phase I trial of intravenous galidesivir

Cybrexa selects CBX-11 as lead clinical development candidate

Arcturus Therapeutics nominates ARCT-810 as development candidate for OTC deficiency

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...